Pharmacology Of Potential Anti-Tumour Agents: Iron Chelators Of The BpT Class
Funder
National Health and Medical Research Council
Funding Amount
$585,455.00
Summary
Pharmacology of Potential Anti-Tumour Agents: Iron Chelators of the BpT Class Cancer cells have a high iron requirement for DNA synthesis and many clinical trials showed Fe chelators are effective anti-cancer drugs. Their potential to act as anti-tumour agents has been confirmed by the entrance of Triapine into widespread NCI clinical trials. In this NHMRC Renewal, we will perform pharmacological and preclinical studies to promote the development of BpT chelators as novel anti-tumour agents.
Industrial Transformation Training Centres - Grant ID: IC170100035
Funder
Australian Research Council
Funding Amount
$4,743,710.00
Summary
ARC Training Centre for Innovation in Biomedical Imaging Technology. The ARC Training Centre for Innovation in Biomedical Imaging Technology expects to train 20 industry-ready innovation scientists who will undertake industry-driven research in the development and application of novel diagnostics, therapeutics and theranostics. They will inform changes in regulatory policy that support industry growth. The Centre will build multidisciplinary links between researchers and within industry to devel ....ARC Training Centre for Innovation in Biomedical Imaging Technology. The ARC Training Centre for Innovation in Biomedical Imaging Technology expects to train 20 industry-ready innovation scientists who will undertake industry-driven research in the development and application of novel diagnostics, therapeutics and theranostics. They will inform changes in regulatory policy that support industry growth. The Centre will build multidisciplinary links between researchers and within industry to develop ‘smart’ probes and ‘smart’ scanning, harnessing the digital revolution for better, cost effective diagnostic imaging and improved health outcomes.Read moreRead less
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE130100164
Funder
Australian Research Council
Funding Amount
$310,000.00
Summary
A facility for ex-vivo molecular imaging. The facility will allow a consortium of Australian researchers to create an integrated facility for imaging biological receptors in tissue, bringing together laboratory, radiochemistry and imaging expertise. Digital data at each site will be able to be viewed and analysed remotely.
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE0989759
Funder
Australian Research Council
Funding Amount
$360,000.00
Summary
Australian Access to and Operation of Advanced Synchrotron Radiation Facilities at the Photon Factory. The primary national benefit of this application will be continued access by peer review for Australian scientists to the advanced synchrotron-radiation capabilities of the Australian National Beamline Facility and other complementary beamlines at the Photon Factory, Japan. This proposal is consistent with the National Research Priorities of An Environmentally Sustainable Australia, Promoting a ....Australian Access to and Operation of Advanced Synchrotron Radiation Facilities at the Photon Factory. The primary national benefit of this application will be continued access by peer review for Australian scientists to the advanced synchrotron-radiation capabilities of the Australian National Beamline Facility and other complementary beamlines at the Photon Factory, Japan. This proposal is consistent with the National Research Priorities of An Environmentally Sustainable Australia, Promoting and Maintaining Good Health and Frontier Technologies for Building and Transforming Australian Industries and will generate science to support and stimulate domestic industry, enhance the domestic knowledge base and international research profile, train students and future synchrotron scientists and foster domestic and international collaborations.Read moreRead less
Industrial Transformation Training Centres - Grant ID: IC210100040
Funder
Australian Research Council
Funding Amount
$4,997,903.00
Summary
ARC Training Centre for Facilitated Advancement of Australia's Bioactives (FAAB). The Centre for Facilitated Advancement of Australia's Bioactives (FAAB) will transform the rapidly growing bioactive ingredients sector. It will apply advanced analytical methods to molecular characterisation of bioactive products derived from foods, food-waste, and cell-based biotechnologies. FAAB will determine modes of action for bioactives with potential lifestyle and nutritional benefits allowing for evidence- ....ARC Training Centre for Facilitated Advancement of Australia's Bioactives (FAAB). The Centre for Facilitated Advancement of Australia's Bioactives (FAAB) will transform the rapidly growing bioactive ingredients sector. It will apply advanced analytical methods to molecular characterisation of bioactive products derived from foods, food-waste, and cell-based biotechnologies. FAAB will determine modes of action for bioactives with potential lifestyle and nutritional benefits allowing for evidence-informed decision-making, and regulatory framework development. FAAB graduates will lead and deliver future national self-reliance to the Australian bioactives sector, increasing diversification and international competitiveness and development of regulation in a growing market. Read moreRead less
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE100100081
Funder
Australian Research Council
Funding Amount
$600,000.00
Summary
Combined scanning tunnelling microscope system for materials characterisation and manipulation at nano scale. The proposed facility is unique in Australia and will substantially enhance national research capabilities in nano-materials, nanotechnology and biotechnology. The proposed infrastructure project will bring more than 20 leading Australian research groups from 10 institutions together to create an outstanding platform to underpin close collaborations among members in a broad field. The pr ....Combined scanning tunnelling microscope system for materials characterisation and manipulation at nano scale. The proposed facility is unique in Australia and will substantially enhance national research capabilities in nano-materials, nanotechnology and biotechnology. The proposed infrastructure project will bring more than 20 leading Australian research groups from 10 institutions together to create an outstanding platform to underpin close collaborations among members in a broad field. The proposed facility will provide significant benefits to Australian researchers in drug design and delivery, nano-material design and characterisation at nano scale for advanced materials, and promotion of renewable energy. This represents a great opportunity to make discoveries and breakthroughs in frontier science and technology in Australia.Read moreRead less
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE170100192
Funder
Australian Research Council
Funding Amount
$450,000.00
Summary
Deep Protein Sequencing, Structure and Quantification Facility. This project aims to establish state-of-the-art complementary mass spectrometers to help research into molecular structure and interactions, post-translational modifications, compound stability and availability within complex biological samples. The facility’s complementary mass spectrometers combine high specificity with high sensitivity and ultrafast scanning, and are expected to rapidly discover, identify and characterise biomole ....Deep Protein Sequencing, Structure and Quantification Facility. This project aims to establish state-of-the-art complementary mass spectrometers to help research into molecular structure and interactions, post-translational modifications, compound stability and availability within complex biological samples. The facility’s complementary mass spectrometers combine high specificity with high sensitivity and ultrafast scanning, and are expected to rapidly discover, identify and characterise biomolecules including peptides, proteins and small molecules. The discovery of unknown compounds is expected to improve fundamental understanding of molecular structure and function, provide opportunities for new bio-industries in health and the environment, and generate commercial opportunities through spin-off companies, patents and licensing.Read moreRead less
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE240100050
Funder
Australian Research Council
Funding Amount
$1,681,491.00
Summary
A national network for magnetic resonance spectroscopy. Our proposed network of high-end facilities for solid-state nuclear magnetic resonance spectroscopy aims to establish cutting-edge capabilities nationally for molecular and materials characterisation. The new infrastructure will enable advanced studies in chemistry, drug design, materials science, and environmental sciences. The expected outcomes include new discoveries, innovative applications, and potential commercialisation of new produc ....A national network for magnetic resonance spectroscopy. Our proposed network of high-end facilities for solid-state nuclear magnetic resonance spectroscopy aims to establish cutting-edge capabilities nationally for molecular and materials characterisation. The new infrastructure will enable advanced studies in chemistry, drug design, materials science, and environmental sciences. The expected outcomes include new discoveries, innovative applications, and potential commercialisation of new products, which will bring significant economic benefits to the Australian economy. Additionally, the network will foster collaborations with international researchers and industry partners in areas of biotechnology, energy capture and storage, and environmental sustainability.Read moreRead less
Probing polynuclear platinum biomolecule interactions. Cancer affects one in four Australians and 50% of cancer patients are treated with cisplatin. BBR3464 is a new type of platinum anticancer drug that has shown promise in clinical trials, including results in cancers that do not respond to cisplatin treatment. Second-generation analogues, now under development, may offer significant advantages. This international collaboration with the inventor of these new drugs puts Australian research at t ....Probing polynuclear platinum biomolecule interactions. Cancer affects one in four Australians and 50% of cancer patients are treated with cisplatin. BBR3464 is a new type of platinum anticancer drug that has shown promise in clinical trials, including results in cancers that do not respond to cisplatin treatment. Second-generation analogues, now under development, may offer significant advantages. This international collaboration with the inventor of these new drugs puts Australian research at the forefront of the clinical development. There is the potential for the generation of new IP from new strategies in the design of improved anticancer drugs. The project builds strong international links and provides international training for Australian PhD students. Read moreRead less